Max-Delbruck-Centrum fur Molekulare Medizin (MDC)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Max-Delbruck-Centrum fur Molekulare Medizin (MDC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013488
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene regulation mechanisms research, and clinical oncology research services. Its other services comprise molecular oncology research, structure and membrane interaction research, genome stability DNA repair and maintenance, haematology research, oncology research, tumorimmunology research, mobile DNA research, cellular neurosciences research, and molecular muscle physiology research services. MDC focuses in the therapeutic areas of cardiovascular and metabolic diseases, cancer, nervous system disorders and medical systems biology. The centre collaborates with Leibniz Institute for Molecular Pharmacology and Charite Universitatsmedizin. MDC is headquartered at Berlin, Germany.

Max-Delbruck-Centrum fur Molekulare Medizin (MDC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 10
Licensing Agreements 12
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 12
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 13
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 14
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 15
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) – Key Competitors 16
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) – Key Employees 17
Max-Delbruck-Centrum fur Molekulare Medizin (MDC) – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Sep 02, 2016: Two MDC researchers win European Research Council Grants 19
Feb 19, 2016: Gene therapy: T cells target mutations to fight solid tumors 20
Product News 21
Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany’s capital city of Berlin 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Key Facts 2
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Deals By Therapy Area, 2011 to YTD 2017 8
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 10
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 12
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 13
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 14
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 15
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Key Competitors 16
Max-Delbruck-Centrum fur Molekulare Medizin (MDC), Key Employees 17

★海外企業調査レポート[Max-Delbruck-Centrum fur Molekulare Medizin (MDC)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Engie Energia Chile SA (ECL):企業の財務・戦略的SWOT分析
    Engie Energia Chile SA (ECL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kolon Industries Inc (120110):企業の財務・戦略的SWOT分析
    Kolon Industries Inc (120110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Seminole Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Seminole Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Industrias Penoles SAB de CV:企業の戦略・SWOT・財務情報
    Industrias Penoles SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Industrias Penoles SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Myriad Genetics, Inc.:企業の戦略・SWOT・財務分析
    Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Cimarex Energy Co (XEC):企業の財務・戦略的SWOT分析
    Cimarex Energy Co (XEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Desktop Genetics Ltd-医療機器分野:企業M&A・提携分析
    Summary Desktop Genetics Ltd (DeskGen) is a provider of genome editing solutions. The company offers software solutions for the design, synthesis and assembly of DNA. It offers deskgen, which is a software system that helps scientists to organize, optimize, and automate their research. DeskGen’s CRI …
  • ICICI Bank Ltd:企業の戦略・SWOT・財務情報
    ICICI Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary ICICI Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Pepsi-Cola Products Philippines Inc:戦略・SWOT・企業財務分析
    Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report Summary Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Tsakos Energy Navigation Ltd (TNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Tsakos Energy Navigation Ltd (TEN), a subsidiary of Tsakos Group, is a marine transportation company that provides transportation services of crude oil, petroleum products and liquefied natural gas (LNG) to national and international oil companies and refineries. It charges customer on time …
  • Ergomed Plc (ERGO):企業の財務・戦略的SWOT分析
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd, is a drug development and clinical research services provider. The company provides various services such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …
  • GoPro, Inc.:戦略・SWOT・企業財務分析
    GoPro, Inc. - Strategy, SWOT and Corporate Finance Report Summary GoPro, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • BioSyent Inc (RX):企業の財務・戦略的SWOT分析
    Summary BioSyent Inc (BioSyent), formerly Hedley Technologies Inc is a specialty pharmaceutical company that offers in-licensing or acquiring innovative pharmaceutical products and technologies to enhance human health. The company’s products include Aguettant System for pre-filled syringes, FeraMAX …
  • Bahamas Petroleum Company Plc (BPC):石油・ガス:M&Aディール及び事業提携情報
    Summary Bahamas Petroleum Company Plc (Bahamas Petroleum), formerly BPC plc, is an oil and gas exploration company. The company invests in an offshore oil exploration programme in licence areas in the territorial waters and maritime Exclusive Economic Zone of The Bahamas. It holds interests in five …
  • The Reject Shop Ltd (TRS):企業の財務・戦略的SWOT分析
    The Reject Shop Ltd (TRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • IMI Plc (IMI):企業の財務・戦略的SWOT分析
    IMI Plc (IMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Ecobliss Holding BV:企業の戦略・SWOT・財務情報
    Ecobliss Holding BV - Strategy, SWOT and Corporate Finance Report Summary Ecobliss Holding BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報
    Summary Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG …
  • Chicago Bridge & Iron Company NV (CBI):電力:M&Aディール及び事業提携情報
    Summary Chicago Bridge & Iron Company NV (CB&I) is a provider of technology and infrastructure solutions. Its services include conceptual design, technology, engineering, procurement, modularization, construction, fabrication, commissioning, maintenance, program management and environmental services …
  • Vyriad Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Vyriad Inc (Vyriad), formerly Omnis Pharma Inc is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company’s pipeline products include various engineered viruses in phase 1 for the treatment of non small cell lun …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆